American Cancer Society® Research Reception
Watch Video
Life SciencesAmerican Cancer Society® Research Reception
GQR and the American Cancer Society® hosted their second annual Research Fundraising Reception on Thursday, June 7 from 6-9PM. The American Cancer Society® (ACS) is a health organization dedicated to eliminating cancer – we are proud to have raised close to $65,000 and 100% of these proceeds went toward ACS’ cancer research efforts.
ACS has helped make possible almost every major cancer research breakthrough since 1946. Bayer and Ipsen Biopharma joined us for an evening of building awareness and networking with life sciences professionals who support the cause.
Our Speakers Included:
- Guest of Honor: Sotirios Stergiopoulos, MD, Chief Medical Officer, Senior Vice President and Head of Global Medical Affairs, Ipsen Biosciences
- Christopher Velis, Founder and Chairman, MedCap Group
- Bob Oliver, President & CEO, V ClinBio; Chairman, Otsuka; Former CEO, Otsuka America Pharmaceuticals
- Robert Forrester, President & CEO, Verastem
- Chloe Lipman, Executive Director, American Cancer Society®
- LaToya Williams, Senior Manager, Primary Health Systems, American Cancer Society®
- Bhavash Ashar, Senior Vice President and Head, U.S. Oncology, Pharmaceuticals division of Bayer, member of the Bayer U.S. Pharma Leadership Team, the Global Oncology Leadership Team and the Group Leadership Circle
This Event took Place at GQR’s New York City Office:
The American Cancer Society is a nationwide voluntary health organization dedicated to eliminating cancer and helping people who face cancer. Learn about cancer research, patient services, early detection, treatment and education at cancer.org.
Bayer AG is a German multinational, pharmaceutical and life sciences company. They help diagnose, alleviate or cure diseases, improve the global food supply and contribute to an active, modern lifestyle.
Ipsen is a French pharmaceutical company headquartered in Paris, France. It primarily develops and markets medications used in oncology, endocrinology and the treatment of neuromuscular disorders.
MedCap invests in the critical issues of global healthcare: developing technologies that reduce suffering, save lives and minimize the cost of healthcare to make it more accessible around the globe. MedCap recently closed its first venture fund in collaboration with one of Harvard Medical School’s top teaching hospitals and research laboratories.
Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients.
